Compare AESI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | PSNL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2023 | 2019 |
| Metric | AESI | PSNL |
|---|---|---|
| Price | $11.69 | $16.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $18.00 | $15.44 |
| AVG Volume (30 Days) | ★ 3.6M | 1.8M |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,310,000.00 | $69,648,000.00 |
| Revenue This Year | $1.44 | $18.40 |
| Revenue Next Year | $16.17 | $33.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.73 | N/A |
| 52 Week Low | $7.64 | $4.96 |
| 52 Week High | $20.13 | $18.89 |
| Indicator | AESI | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 51.30 |
| Support Level | $10.78 | $15.92 |
| Resistance Level | $12.37 | $16.39 |
| Average True Range (ATR) | 0.71 | 0.38 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 26.81 | 34.50 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.